LifeSci Venture Partners — 2024 Investments

1 investments dated 2024 · listed companies and verified rows first · show all

Candid Therapeuticscandidrx.com inAug 2024

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.

BiotechHealthtechSan Diego, US

Ken Song(Chairman, President and CEO)inKenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)

BoardJeffrey Tong, Ph.D.(Director)

Co-investorsForesite Capital OrbiMed Samsara BioCapital TCG Crossover Third Rock Ventures venBio Partners +2 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.